Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 8 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03879629 | Treating Breast Cancer Patients Undergoing Trastuzumab Treatment With Carvedilol to Reduce Incidence of Heart Failure | terminated | Phase 2 | 224 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04695977 | CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma | terminated | Phase 2 / Phase 3 | 20 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05453396 | Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies | terminated | Phase 2 | 11 | University of WashingtonOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05597878 | Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy | terminated | Phase 2 / Phase 3 | 58 | Wake Forest University Health SciencesOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01148056 | Intensity Modulated Radiation Therapy (IMRT) for Patients With Rectal Cancer | terminated | N/A | 2 | Massachusetts General HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02602756 | Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas(HYGROMEL) | terminated | N/A | 32 | Centre Antoine LacassagneOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | terminated | Phase 2 | 648 | Spectrum Pharmaceuticals, IncINDUSTRY | 8 | Jun 12, 2026 | clinicaltrials |
| NCT05549921 | Phase II Study of TAEST16001 in Soft Tissue Sarcoma | terminated | Phase 2 | 8 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | terminated | Phase 2 | 7 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06188208 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors | terminated | Phase 1 | 132 | Vividion Therapeutics, Inc.INDUSTRY | 3 | Jun 12, 2026 | clinicaltrials |
| NCT02409316 | [18F]FES PET/CT in Endocrine Refractory Breast Cancer | terminated | Phase 2 | 6 | University of PennsylvaniaOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03866109 | A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT(TEM-GBM) | terminated | Phase 1 / Phase 2 | 25 | Genenta ScienceINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04745871 | Diagnostic Performance of PSMA PET/CT for Pre-operative Lymph Node Assessment in Intermediate and High-risk Non-metastasic Prostate Cancer (PREOP-PSMA ).(PREOP-PSMA) | terminated | N/A | 112 | University Hospital, BrestOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04984811 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | terminated | Phase 2 | 33 | NeoImmuneTechINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05744739 | Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06158516 | A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors | terminated | Phase 2 | 6 | Changhai HospitalOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06505122 | Dyadic Life Review Intervention for Older Patients With Advanced Cancer) and Their Caregivers(DLR RCT) | terminated | N/A | 6 | University of RochesterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05025423 | Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06267001 | A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy(SKYSCRAPER-15) | terminated | Phase 3 | 56 | Hoffmann-La RocheINDUSTRY | 11 | Jun 10, 2026 | clinicaltrials |
| NCT03637335 | Comparing Palliative Radiotherapy With or Without Carboplatin(METAXIOM) | terminated | Phase 3 | 26 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04916002 | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer | terminated | Phase 2 | 77 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jun 9, 2026 | clinicaltrials |
| NCT03146871 | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent | terminated | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03674515 | Study of Program Interest "Bouge" to Improve the Daily Physical Activity in Processings Treatment of Non-metastatic Breast Cancer(BOUGE CANCER) | terminated | N/A | 23 | University Hospital, BrestOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT03676478 | Assessing Timing of Enteral Feeding Support in Esophageal Cancer Patients on Muscle functTion and Survival(EFECTS) | terminated | N/A | 239 | University Hospital, GasthuisbergOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04994977 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery | terminated | Phase 1 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06299761 | Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications(STARMAP) | terminated | Phase 1 | 19 | Boundless Bio, Inc.INDUSTRY | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04748419 | Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab | terminated | Phase 1 / Phase 2 | 6 | University of NebraskaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05110781 | Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site | terminated | Phase 2 | 1 | University of California, DavisOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05712278 | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 7 | SanofiINDUSTRY | 1 | Jun 5, 2026 | clinicaltrials |
| NCT05824689 | Fluoroquinolone Resistance Prevalence Study(FRE) | terminated | — | 124 | Hackensack Meridian HealthOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06381830 | Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 8 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | terminated | Phase 2 | 11 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03632941 | A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer | terminated | Phase 2 | 8 | Herbert LyerlyOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04085237 | ESP Block for Laparoscopic Nephrectomy Surgeries(ESPB) | terminated | N/A | 10 | McMaster UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04189614 | An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer | terminated | Phase 1 | 65 | AbbVieINDUSTRY | 6 | Jun 4, 2026 | clinicaltrials |
| NCT04729387 | Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected | terminated | Phase 3 | 358 | Novartis PharmaceuticalsINDUSTRY | 26 | Jun 4, 2026 | clinicaltrials |
| NCT04800822 | PF-07284892 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 53 | PfizerINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05183828 | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | terminated | Phase 4 | 62 | University of WashingtonOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05316467 | Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma | terminated | Phase 2 / Phase 3 | 8 | Xiaojun ChenOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05949632 | A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 5 | Incyte CorporationINDUSTRY | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06351332 | ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | terminated | Phase 1 | 7 | Filipa Lynce, MDOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT02676050 | Visualising c-MET and Activated Neutrophils in Lung Cancer(DUAL) | terminated | Early Phase 1 | 5 | University of EdinburghOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03958383 | IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma | terminated | Phase 1 / Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05062980 | Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer(Acclaim-2) | terminated | Phase 1 | 5 | Genprex, Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05523440 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | terminated | Phase 2 | 9 | University of OklahomaOTHER | 1 | Jun 3, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2026source: clinicaltrials